INTRODUCTION
• There is limited clinical data on scanning-beam proton therapy (SPT) in treating locally-advanced lung cancer, and increasing interest in whether dosimetric advantages of can translate into superior clinical outcomes over photon therapy.
• We present our experience of SPT and photon intensitymodulated radiation therapy (IMRT) with real-life dosimetry, and outcomes in patients with stage III lung cancer.
METHODS
• Patients with stage III lung cancer treated at our center between 2013-May 2018 were identified in compliance with an IRBapproved study (64 patients=34 SPT +30 IMRT).
• Most proton patients were treated with pencil beam scanning (28/34), 6/34 with uniform scanning.
• Fisher's exact test, Chi-square test, and Mann-Whitney test were used to compare groups. All tests were two-sided.
RESULTS
• Mean dose to lung, heart, and esophagus were lower in the SPT group, with most benefit in the low dose region ( Fig. 1 &Table 2).
• Grade 2+ pneumonitis rate was 21% in the SPT group and 40% in the IMRT group (p=0.1). Esophagitis and dermatitis grades were not different between the two groups (Table 3 ).
• Overall survival and progression free-survival were not different between SPT and IMRT.
CONCLUSIONS
• Scanning beam proton therapy in stage III lung cancer can lower dose to normal organs compared with IMRT.
• There is no statistically significant difference in toxicity rates or survival, although there may be a trend towards less pneumonitis. Table 3 . Treatment Toxicities.
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